DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4mgggt/egp437_dry_eye) has announced the addition of the "EGP-437 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022" report to their offering.
Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.
The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
Eyegate Pharma is developing EGP-437 for the treatment of multiple ocular diseases, including DES, anterior uveitis, scleritis, non-necrotizing anterior scleritis, and corneal graft rejection. EGP-437 is a reformulated dexamethasone phosphate solution that uses a proprietary novel drug delivery system called the EyeGate II Delivery System (EGDS), which is a transcleral iontophoresis delivery platform. Iontophoresis is a non-invasive ocular drug delivery method that involves the application of a mild electrical field to the therapeutic.
This increases its penetration into both the anterior and posterior tissues of the eye, while at the same time minimizing systemic distribution and its associated side effects. EGP-437 is a glucocorticoid receptor agonist that has been shown to reduce inflammation by inhibiting cytokines interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1).
- Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on EGP-437 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for EGP-437 for the top two countries from 2012 to 2022.
- Sales information covered for Japan and China.
For more information visit http://www.researchandmarkets.com/research/4mgggt/egp437_dry_eye
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.